Beam Therapeutics Inc BEAM

US Biotechnology

$24.27 ▼ -1.58% ($-0.39)

🔥 High Short Interest 🎢 High Beta

Open $24.97

Prev Close $24.66

Day Range $23.75 – $24.97

52W Range $20.23 – $38.26

Market Cap $2.51B

Beta 2.27

EPS (TTM) $-0.81

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-02-06
Shares Out.	102,880,000
Website	beamtx.com/ ↗
Phone	13026587581
Employees	540
Revenue	$490,000
Gross Profit	$490,000
Net Income	-$122.7M
Free Cash Flow	-$372.8M
Total Assets	$1.39B
Total Liabilities	$318.9M
Equity	$1.07B

About Beam Therapeutics Inc

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Beam Therapeutics Inc is a publicly traded company under the ticker symbol BEAM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.